Biomaterials Stock Soars 542% on 23x Revenue Surge

A 23-fold revenue surge. A 542% stock spike. And a deal with a beauty giant.

Some companies are built to thrive in the year ahead — and I’ve pinpointed seven of the best.

They’re in sectors already showing signs of acceleration, and the timing couldn’t be better.

This isn’t guesswork — it’s research-backed, easy to follow, and completely free.

In the guide, you’ll see:

The market moves fast — the best time to act is before the crowd.

[Claim Your Free Report Now]

U.S. stocks rose today as in-line inflation data reinforced expectations for a September Federal Reserve rate cut, boosting investor confidence despite mixed earnings reports.

Amazon is making one of its most aggressive moves yet into the grocery market, expanding same-day delivery of perishable goods to Prime members in more than 1,000 U.S. cities and towns.

This will follow the plans to more than double that footprint by the end of the year.

The rollout integrates fresh groceries, from produce to dairy, directly into Amazon's existing logistics network, allowing customers to add food items to their standard Amazon orders and receive them within hours.

This expansion significantly deepens Amazon's reach into the $1 trillion grocery sector, which has long been dominated by Walmart, Kroger, and Target.

For current shareholders, the move signals a broader monetization of Amazon's logistics infrastructure, leveraging its Prime membership base to capture higher-frequency purchase categories.

For those considering an entry position, the shift demonstrates how Amazon can pressure incumbents while increasing the switching costs for consumers already locked into its ecosystem.

By integrating perishables into the core Amazon platform rather than keeping them siloed within Amazon Fresh or Whole Foods, the company could drive operational efficiency and boost basket sizes.

Competitors' share prices fell after the announcement, highlighting the market's perception that this is not a test but a long-term strategy.

Your portfolio may already be in the green, but why stop there?

This free special report reveals five carefully selected stocks with the potential to double or more in the coming year.

They’ve been screened for growth potential, solid balance sheets, and technical strength — qualities that can set the stage for big moves.

Opportunities like this don’t stay under the radar for long.

Get your free copy today before access expires at midnight.

*This free resource is being sent by Zacks. We identify investment resources you may choose to use in making your own decisions. Use of this resource is subject to the Zacks Terms of Service.
*Past performance is no guarantee of future results. Investing involves risk. This material does not constitute investment, legal, accounting, or tax advice. Zacks Investment Research is not a licensed dealer, broker, or investment adviser.

UnitedHealth Group (NYSE: UNH) has secured a key regulatory green light for its $3.3 billion acquisition of home-health provider Amedisys, paving the way for a significant expansion into one of healthcare’s fastest-growing markets.

The move follows a settlement with the U.S. Department of Justice that includes divesting 164 locations to preserve competition.

For UnitedHealth, the acquisition is more than just an asset grab.

Home healthcare is emerging as a strategic battleground as the U.S. population ages and payers look to reduce hospital utilization.

By integrating Amedisys into its Optum division, UnitedHealth gains a larger footprint in a sector that can lower costs, improve patient outcomes, and capture more value across the healthcare delivery chain.

It’s also a way to counteract current industry headwinds, including rising medical expenses and tighter margins in Medicare Advantage.

For those watching the stock, the deal positions UnitedHealth to strengthen recurring revenue streams in a segment with strong demographic tailwinds.

It could also deepen patient engagement and cross-sell opportunities across its insurance and care businesses.

The challenge will be executing scaling services efficiently while managing the regulatory scrutiny that comes with market leadership.

If the integration goes smoothly, UnitedHealth could emerge with an even more durable growth engine at a time when diversification is key to sustaining performance in the healthcare sector.

I just got my hands on a short list of 7 stocks that almost never make it into public view this early.

These aren’t “maybe someday” plays.

They’re set up for potential movement over the next 30 days — and the window is already opening.

Normally, this kind of data stays behind closed doors.

But I convinced my contact to let me share it.

Download it before they change their minds.

[Get Your Copy Here]

When a stock pulls back 15% in just a few weeks, it's easy for investors to get nervous. However, the recent drop in shares of IBM (NYSE: IBM) is a different story altogether.

The company is now displaying a key buy signal that has not been seen since before its last major rally, suggesting this could be a moment of opportunity rather than a cause for concern.

IBM's strong Q2 report supports this bullish perspective. The company reported nearly 8% year-over-year revenue growth, expanded its margins, and raised its full-year guidance.

With the growth of IBM's generative AI business into a $7.5 billion enterprise, the company highlights its successful strategic shift.

The market's focus on a minor shortfall in the software segment seems an overreaction, overshadowing the company's strong overall performance.

The most compelling aspect of this narrative is the stock's technical setup. The sell-off has driven IBM's Relative Strength Index (RSI) down to an extremely oversold level of 27.

This is the exact same signal that preceded the company's multi-month rally that delivered over 30% in gains the last time it occurred.

With the share price now finding its footing and consolidating around the key $250 level, it suggests the bearish momentum may be exhausted.

This rare technical signal, combined with solid fundamentals, presents a compelling argument that a rebound could be on the horizon.

👉 Click here to get our closing report to your cell for free!

Bolt Projects Holdings Inc [BSLK] $14.00 (+542.20%)

Bolt Projects surged after Q2 revenue of its Vegan Silk Technology Platform jumped 23-fold year-over-year, beating internal profit timelines and securing its first major beauty conglomerate customer.

WEBTOON Entertainment Inc [WBTN] $16.96 (+81.20%)

WEBTOON Entertainment jumped after announcing a multi-year Disney partnership to bring 100 Marvel, Star Wars, and 20th Century Studios titles to its platform, alongside a surprise quarterly profit.

Generation Bio Co [GBIO] $6.61 (+63.21%)

Generation Bio rose after unveiling breakthrough preclinical data that validated its targeted genetic delivery platform, reinforcing its lead in T-cell-directed therapies.

Vicarious Surgical Inc [RBOT] $7.88 (-23.89%)

Vicarious Surgical fell after posting another steep quarterly loss, reporting a $13.4 million cash burn in Q2, and guiding for full-year burn of about $50 million, fueling liquidity concerns despite a CEO transition.

KinderCare Learning Companies Inc [KLC] $7.62 (-22.38%)

KinderCare slipped after Q2 occupancy softened late in the quarter, prompting a cut to full-year revenue and EBITDA guidance despite modest revenue growth and higher net income.

BioXcel Therapeutics Inc [BTAI] $5.60 (-17.65%)

BioXcel dropped after missing both revenue and EPS estimates, reporting just $0.12 million in sales and a wider quarterly loss than analysts expected, despite prior positive estimate revisions.

The U.S.-China trade rift is rewriting the AI playbook.

While some major players are scrambling, others are stepping into the spotlight.

We’ve zeroed in on 9 U.S.-based AI companies that could fill the gap — fast.

Their tech is already in place, and the timing couldn’t be better.

This free report shows you who they are before everyone else catches on.

[See All 9 Here]

That's it for today! Please, write us back, and let us know what you think of the Closing Bell Roundup. We're always eager to hear feedback!

Thanks for reading. I'll see you at the next open! 

Best Regards,
— Adam G.
Elite Trade Club

Click here to get our daily newsletter straight to your cell for free.

P.S. Just like this newsletter, it's 100% free*, and you can stop at any time by replying STOP.